Quick Answer
Karyopharm Therapeutics Inc. reported Operating Income of -$90.71 million for fiscal year 2025.
Karyopharm Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$90.71M | +24.1% |
| 2024 | -$119.44M | +7.8% |
| 2023 | -$129.54M | +8.9% |
| 2022 | -$142.20M | -44.7% |
| 2021 | -$98.27M | +42.8% |
| 2020 | -$171.85M | +9.2% |
| 2019 | -$189.28M | -5.2% |
| 2018 | -$179.88M | -37.8% |
| 2017 | -$130.54M | -17.9% |
| 2016 | -$110.73M | +7.0% |
| 2015 | -$119.08M | -57.0% |
| 2014 | -$75.85M | -123.4% |
| 2013 | -$33.95M | -113.7% |
| 2012 | -$15.89M | -54.1% |
| 2011 | -$10.31M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$15.22M | +42.1% | +37.6% |
| June 30, 2025 | -$24.39M | +13.3% | +26.7% |
| March 31, 2025 | -$33.26M | +1.5% | -26.5% |
| September 30, 2024 | -$26.28M | +15.9% | +6.5% |
| June 30, 2024 | -$28.12M | +4.9% | +16.7% |
| March 31, 2024 | -$33.76M | -9.3% | -8.0% |
| September 30, 2023 | -$31.26M | -1.4% | -5.7% |
| June 30, 2023 | -$29.57M | +31.1% | +4.3% |
- Karyopharm Therapeutics Inc. showed an increase of +24.1% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, Karyopharm Therapeutics Inc.’s operating income has declined by 779.7% (from -$10.31 million to -$90.71 million).
- The most recent figure is from Karyopharm Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: